Neonatal vaccination primes persistent HIV Env-specific antibodies that are augmented by a single booster immunization in late infancy

Abstract

Abstract Breastmilk transmission of HIV remains unacceptably high. Vaccine approaches that prime robust virus-specific immune responses in infancy may prevent acquisition during the breastfeeding period. Moreover, vaccine responses that generate robust immunological memory that persists into adolescence could prevent sexual transmission later in life. The current study investigated the immunological benefit of late boosting following vaccination in infancy. Two groups of neonatal rhesus macaques were immunized with a clade C HIV Env protein adjuvanted with 3M-052 stable emulsion (SE) vaccine (Env Only) alone or together with a modified vaccinia Ankara (MVA) vector expressing HIV Env and SIV Gag (MVA/Env) at 0, 6, and 12 weeks of age. Env-specific B cells were present in blood yet absent from lymph nodes in the Env Only group by week 14. At week 32, 18 weeks following the last immunization, we could still detect Env-specific plasma IgG responses capable of autologous and heterologous HIV Env binding, Env-specific ADCC activity and CD4 blocking in both groups. A final booster immunization at week 32 enhanced avidity and function of Env-specific plasma IgG in both groups. These data confirmed previous work by our group that demonstrated HIV Env protein adjuvanted with the TLR7/8-based 3M-052-SE primed greater immune responses than Span85-Tween 80 Squalene. Our data from the Env Only vaccine regimen are consistent with the induction of Env-specific antibody responses in human infants. These results support the idea that early life vaccination is an effective means to induce persistent HIV Env-specific IgG responses that can be boosted in infancy and could be exploited to drive protective immunity against HIV acquisition prior to sexual debut.